{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:06:50Z","timestamp":1747181210867,"version":"3.40.5"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"43","license":[{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,27]]},"abstract":"<jats:p>To investigate associations between inosine triphosphatase (ITPA) gene polymorphisms and long-term outcomes among chronic hepatitis C (CHC) patients in Northeast China treated with Peg-interferon (IFN)\/ribavirin (RBV). CHC patients who received Peg-IFN-2a\/RBV treatment during between 2011 and 2013 at 5 hepatitis centers in Northeast China were enrolled. ITPA single nucleotide polymorphisms rs1127354 and rs7270101 from all patients were detected and their associations with 5-year outcomes were analyzed. A total of 635 patients, including 421 infected with hepatitis C virus (HCV) genotype 1 and 214 infected with non-genotype 1 were included. No significant differences were observed in the distribution frequencies of ITPA rs1127354 variants and ITPase activity between patients with HCV genotype 1 and non-genotype 1. In patients who received more than 80% of the planned RBV dose, the 5-year virological response rate and the improvement in liver fibrosis were higher in those with ITPA rs1127354 non-CC with ITPase activity &lt;25% compared with these outcomes in patients with ITPA rs1127354 CC with 100% ITPase activity. Multiple regression analysis revealed that HCV genotype non-1, low baseline HCV ribose nucleic acid (RNA) levels (\u22644\u2009\u00d7\u200910<jats:sup>5<\/jats:sup> IU\/mL), interleukin-28B rs12979860 CC genotype, low baseline liver fibrosis (Fibroscan 0-2), and ITPA rs1127354 non-CC genotype were independent predictors for a high long-term virological response rate, whereas interleukin-28B rs12979860 CC genotype, ITPA rs1127354 non-CC genotype, and low baseline liver fibrosis were independent predictors for improvement of liver fibrosis. ITPA rs1127354 polymorphisms is predictors of long-term outcomes in CHC patients treated with Peg-IFN\/RBV.<\/jats:p>","DOI":"10.1097\/md.0000000000035508","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T23:07:16Z","timestamp":1707520036000},"page":"e35508","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Associations of ITPA gene polymorphisms with outcomes among chronic hepatitis C patients treated with Peg-interferon\/ribavirin: A 5-year follow-up study"],"prefix":"10.1097","volume":"102","author":[{"given":"Zhenhua","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, The Third Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanxin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Third Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Third Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Jilin Institute for Drug Control, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Wang","sequence":"additional","affiliation":[{"name":"College of Food Science and Engineering, Northwest A&F University, Yangling, Shanxi, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinwei","family":"Xu","sequence":"additional","affiliation":[{"name":"Huanan Agricultural Technology Extension Center, Huarong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyu","family":"Ma","sequence":"additional","affiliation":[{"name":"Sichuan Tianzow Breeding Co., Ltd, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0392-1126","authenticated-orcid":false,"given":"Jiangbin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Digestive, China-Japan Union Hospital Affiliated to Jilin University, Changchun, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2217\/14622416.8.9.1221","article-title":"Pharmacogenetic significance of inosine triphosphatase.","volume":"8","author":"Bierau","year":"2007","journal-title":"Pharmacogenomics"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s00439-002-0798-z","article-title":"Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency.","volume":"111","author":"Sumi","year":"2002","journal-title":"Hum Genet"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ymgme.2005.03.011","article-title":"Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population.","volume":"85","author":"Maeda","year":"2005","journal-title":"Mol Genet Metab"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1373\/clinchem.2005.059501","article-title":"Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population.","volume":"52","author":"Shipkova","year":"2006","journal-title":"Clin Chem"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1872-034X.2010.00741.x","article-title":"ITPA gene variant protects against anemia induced by pegylated interferon-\u03b1 and ribavirin therapy for Japanese patients with chronic hepatitis C.","volume":"40","author":"Sakamoto","year":"2010","journal-title":"Hepatol Res"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3346\/jkms.2013.28.8.1213","article-title":"The impact of inosine triphosphatase variants on hemoglobin level and sustained virologic response of chronic hepatitis C in Korean.","volume":"28","author":"Kim","year":"2013","journal-title":"J Korean Med Sci"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1053\/j.gastro.2010.06.016","article-title":"Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.","volume":"139","author":"Thompson","year":"2010","journal-title":"Gastroenterology"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1097\/MEG.0b013e3283546efd","article-title":"Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2\/G3 cohort.","volume":"24","author":"Eskesen","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s00535-016-1279-9","article-title":"ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C.","volume":"52","author":"Morio","year":"2017","journal-title":"J Gastroenterol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s12072-015-9654-9","article-title":"Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin.","volume":"10","author":"Nakayama","year":"2016","journal-title":"Hepatol Int"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1002\/hep.27009","article-title":"Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2\/3.","volume":"59","author":"Rembeck","year":"2014","journal-title":"Hepatology"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.","volume":"65","author":"Reig","year":"2016","journal-title":"J Hepatol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"e41933","DOI":"10.5812\/hepatmon.41933","article-title":"The risk of hepatocellular carcinoma after directly acting antivirals for Hepatitis C virus treatment in liver transplanted patients: is it real?","volume":"16","author":"Strazzulla","year":"2016","journal-title":"Hepat Mon"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/liv.13390","article-title":"Increased incidence of liver cancer after successful DAA treatment of chronic hepatitis C: fact or fiction?","volume":"37","author":"Alberti","year":"2017","journal-title":"Liver Int"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/jvh.12726","article-title":"The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: a Belgian experience.","volume":"24","author":"Bielen","year":"2017","journal-title":"J Viral Hepat"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"e0167934","DOI":"10.1371\/journal.pone.0167934","article-title":"DAAs rapidly reduce inflammation but increase serum VEGF level: a rationale for tumor risk during anti-HCV treatment.","volume":"11","author":"Villani","year":"2016","journal-title":"PLoS One"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"e7554","DOI":"10.1097\/MD.0000000000007554","article-title":"The relationship between ITPA rs1127354 polymorphisms and efficacy of antiviral treatment in Northeast Chinese CHC patients.","volume":"96","author":"Liu","year":"2017","journal-title":"Medicine (Baltim)"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"EASL clinical practice guidelines: management of hepatitis C virus infection.","volume":"55","year":"2011","journal-title":"J Hepatol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL recommendations on treatment of hepatitis C 2015.","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"R21-20250504","first-page":"179","article-title":"Sofosbuvir, pegylated interferon and ribavirin in the treatment of an Egyptian cohort with Hepatitis C virus infection in real-life clinical practice.","volume":"19","author":"Abd-Elsalam","year":"2019","journal-title":"Infect Disord Drug Targets"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2174\/1871526517666170417143216","article-title":"Efficacy of Sofosbuvir plus ribavirin with or without Peginterferon-Alfa in treatment of a cohort of Egyptian patients with hepatitis C virus infection.","volume":"17","author":"Ahmed","year":"2017","journal-title":"Infect Disord Drug Targets"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2174\/1871526517666170606103533","article-title":"Association of IL-12 B gene polymorphism with staging of liver disease in chronic HCV patients.","volume":"18","author":"Elwan","year":"2018","journal-title":"Infect Disord Drug Targets"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature08825","article-title":"ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.","volume":"464","author":"Fellay","year":"2010","journal-title":"Nature"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.","volume":"65","author":"Conti","year":"2016","journal-title":"J Hepatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:10:51Z","timestamp":1746328251000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,27]]},"references-count":25,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035508","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2023,10,27]]}}}